KYORIN Pharmaceutical (4569) · InitiativeFirst statedLatest Financial results presentation (2026-07-30): "Advanced"
In-Licensing KRP-126 (BDT272)
First written in FY2026. 1 of 2 entries say "Advanced", first in 2026-07-30. Latest entry: 2026-07-30.
2entries
1years
1from disclosures
How it moved
Same theme, other companies
Introduction of KRP-126 (BDT272) from ビオドールA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-07-30AdvancedFinancial results presentation
「KRP-126 Neuropathic pain Phase 1 Domestic Phase 1 scheduled to start in FY2026」
Following the initial disclosure of the license agreement, KRP-126 was specified as being in development, with a domestic Phase 1 trial scheduled to begin in FY2026. The original thread remains unchanged. - FY2026First statedAnnual report
「In March 2026, we entered into a license agreement with Biodol for KRP-126 (BDT272), a drug candidate for neuropathic pain, and a license agreement with UBE Corporation for a novel drug candidate.」
A license agreement for the neuropathic pain drug candidate KRP-126 (BDT272) was signed with Biodol in March 2026.